Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
|Videos|December 14, 2017
Building Relationships with Prescribers Is Needed to Improve Patient Care
In this video, Tripp Logan, PharmD, explains how pharmacists can establish solid relationships with other providers to maximize the management of patients' diabetes.
Advertisement
In this video, Tripp Logan, PharmD, explains how pharmacists can establish solid relationships with other providers to maximize the management of patients' diabetes. He explains that pharmacists should first focus on building the relationship through sharing common patient goals, and then initiating conversation about optimizing therapy for the patient.
Advertisement
Related to this article
Novo's topline phase 3 data show 12.4% weight loss with CagriSema 1.0 mg/1.0 mg in type 2 diabetes and 21.0% in adults with overweight or obesity.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
3
Ramantamig's 93.6% ORR and Outpatient CRS Control
4
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
5